Description

Simple

Information currently not available.

Clinical

Information currently not available.

Overview

Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.

Pharmacology

Indication

For the treatment of clinical depression.

Pharmacodynamic

Reboxetine is a selective noradrenaline reuptake inhibitor (NaRI), the first drug of new antidepressant class. Reboxetine is an a-ariloxybenzyl derivative of morpholine. Reboxetine is primarily used to treat depression but has also been found useful in the treatment of narcolepsy and panic disorders... Read more

Mechanism of action

Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affin... Read more

Absorption

Reboxetine is rapidly and extensively absorbed following oral administration.

Protein binding

98%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

12.5 hours

Route of elimination

Information currently not available.

Toxicity

Reports of seizures (rare) have been reported

Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Insomnia US
  • Kind: experimental
    • Percent: 21-39%
  • Kind: placebo
    • Percent: 7-23%
  • Clinical Trial
    Dry Mouth US
  • Kind: experimental
    • Percent: 15-32%
  • Kind: placebo
    • Percent: 5-19%
  • Clinical Trial
    Constipation US
  • Kind: experimental
    • Percent: 17-21%
  • Kind: placebo
    • Percent: 5-20%
  • Clinical Trial
    Headache US
  • Kind: experimental
    • Percent: 9-15%
  • Kind: placebo
    • Percent: 2-13%
  • Clinical Trial
    Tachycardia US
  • Kind: experimental
    • Percent: 4-13%
  • Kind: placebo
    • Percent: <1-7%
  • Clinical Trial
    Sweating US
  • Kind: experimental
    • Percent: 9-13%
  • Kind: placebo
    • Percent: 2-8%
  • Clinical Trial
    Hyperhidrosis US
  • Kind: experimental
    • Percent: 12%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: 4-11%
  • Kind: placebo
    • Percent: <7%
  • Clinical Trial
    Myocardial Ischemia US
  • Kind: experimental
    • Percent: 1-10%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Dizziness US
  • Kind: experimental
    • Percent: 2-9%
  • Kind: placebo
    • Percent: 4-5%
  • Clinical Trial
    Tremor US
  • Kind: experimental
    • Percent: 2-3%
  • Kind: placebo
    • Percent: 1-9%
  • Clinical Trial
    Agitation US
  • Kind: experimental
    • Percent: 2-6%
  • Kind: placebo
    • Percent: <1%
  • Clinical Trial
    Decreased appetite US
  • Kind: experimental
    • Percent: 6%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Anxiety US
  • Kind: experimental
    • Percent: 4-5%
  • Kind: placebo
    • Percent: <4%
  • Clinical Trial
    Diarrhea US
  • Kind: experimental
    • Percent: 2-3%
  • Kind: placebo
    • Percent: <5%
  • Clinical Trial
    Paresthesia US
  • Kind: experimental
    • Percent: 3-5%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Abdominal Pain US
  • Kind: experimental
    • Percent: 2-5%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Vasodilatation US
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: <1%
  • Clinical Trial
    Asthenia US
  • Kind: experimental
    • Percent: 3-4%
  • Kind: placebo
    • Percent: 2-3%
  • Clinical Trial
    Nervousness US
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Dysuria US
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: <1%
  • Clinical Trial
    Accommodation disorder US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1-4%
  • Clinical Trial
    Somnolence US
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 4%
  • Clinical Trial
    Decreased libido US
  • Kind: experimental
    • Percent: 1-2%
  • Kind: placebo
    • Percent: <4%
  • Clinical Trial
    Palpitation US
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Erectile Dysfunction US
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: <1%
  • Clinical Trial
    Urinary Retention US
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: <1%
  • Clinical Trial
    Rash US
  • Kind: experimental
    • Percent: 1-3%
  • Kind: placebo
    • Percent: <1%
  • Clinical Trial
    Dyspepsia US
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Hypertension US
  • Kind: experimental
    • Percent: 1-3%
  • Kind: placebo
    • Percent: <3%
  • Clinical Trial
    Chills US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: <1%
  • Clinical Trial
    Dysgeusia US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Ejaculation disorder US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: <1%
  • Clinical Trial
    Vomiting US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Hypotension US
  • Kind: experimental
    • Percent: 1-2%
  • Kind: placebo
    • Percent: <2%
  • Clinical Trial
    Pharyngitis US
  • Kind: experimental
    • Percent: 1-2%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Bronchitis US
  • Kind: experimental
    • Percent: 1-2%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    GGT increased US
  • Kind: experimental
    • Percent: <2%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Viral Infection US
  • Kind: experimental
    • Percent: 1-2%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Flu syndrome US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Cerebral Ischemia US
  • Kind: experimental
    • Percent: <2%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Hypercholestermia US
  • Kind: experimental
    • Percent: 1-2%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Hyperlipemia US
  • Kind: experimental
    • Percent: <2%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Libido decreased US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: <1%
  • Clinical Trial
    Akathisia US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: <1%
  • Clinical Trial
    Pyrexia US
  • Kind: experimental
    • Percent: 0.1-1%
  • Clinical Trial
    Pollakiuria US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Weight decreased US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: <1%
  • Clinical Trial
    Hair color changes US
  • Kind: experimental
    • Percent: 0.1-1%
  • Clinical Trial
    Vertigo US
  • Kind: experimental
    • Percent: 0.1-1%
  • Clinical Trial

    Contraindications

    • Regions: US
    • Patient Conditions:
        • Name: Narrow angle glaucoma
        • Drugbank Id: DBCOND0104923
    • Regions: US
    • With Categories:
        • Name: Monoamine Oxidase Inhibitors
        • Drugbank Id: DBCAT001004
        • Mesh Id: D008996

    Food Interactions

    Information currently not available.